Genprex Inc. (GNPX) SEC News Jan. 06, 2026, 12:03 UTC (75% Positive) GENPREX, INC. (GNPX) Announces Clinical Development Update Full text
Register to leave comments News bot Jan. 6, 2026, 12:04 p.m. 📋 GENPREX, INC. (GNPX) - Clinical Trial Update Filing Date: 2026-01-06 Accepted: 2026-01-06 07:03:02 Event Type: Clinical Trial Update Event Details: Genprex Inc. (GNPX) Announces Clinical Trial Update Genprex Inc. (GNPX) provided an update on its clinical development programs. Clinical Development Highlights: Collaboration: I.R.S. Employer Identification Number 🔬 Clinical Development Pipeline (GENPREX, INC.): Product Type Development Stage Therapeutic Area Source Platinum-Based Chemotherapy DRUG Phase PHASE1 Carcinoma, Non-Small Cell Lung ClinicalTrials.gov osimertinib DRUG Phase PHASE1 Carcinoma, Non-Small Cell Lung ClinicalTrials.gov quaratusugene ozeplasmid BIOLOGICAL Phase PHASE1 Carcinoma, Non-Small Cell Lung ClinicalTrials.gov atezolizumab BIOLOGICAL Phase PHASE1 Small Cell Lung Cancer Extensive Stage ClinicalTrials.gov 💼 Business Developments: PartnershipAcquisition: Not availableLicensing: Not availableRegulatory ApprovalExecutive Changes: Not available Structured Data: Company Name: Genprex Inc.CIK: 0001595248Ticker Symbol: GNPXPeriod End Date: 2026-01-06Document Type: 8-K
📋 GENPREX, INC. (GNPX) - Clinical Trial Update
Filing Date: 2026-01-06
Accepted: 2026-01-06 07:03:02
Event Type: Clinical Trial Update
Event Details:
🔬 Clinical Development Pipeline (GENPREX, INC.):
💼 Business Developments:
Structured Data: